News Formal

Roche Aims to Capitalize on Obesity-Drug Market as It Seeks Recovery Amid Sector Turmoil

  • 📰 IrishTimes
  • ⏱ Reading Time:
  • 20 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 35%
  • Publisher: 98%

Business And Finance News

Roche,Obesity Drugs,Carmot Acquisition

Swiss pharmaceutical giant Roche is making a major move in the obesity-drugs market by acquiring Carmot for up to $3.1 billion. The company hopes this acquisition will help it regain a leading position in an area expected to grow to $200 billion by 2031, following a period of decline.

Investors who have been enduring a turbulent ride since Malin's flotation in March 2015, now face a potential end to the uncertainty as Roche eyes a recovery in the obesity-drugs market. Roche, previously underperforming and grappling with declining sales of its COVID-19 test kits and drug candidate failures, has made a significant move this year by acquiring Carmot for up to $3.1 billion.

This acquisition comes as the obesity-drugs market is projected to grow significantly, reaching an estimated $200 billion by 2031. The wider pharmaceutical sector, meanwhile, has been dealing with the repercussions of Donald Trump's re-election and the proposed appointment of an anti-vaccine activist as his health secretary, which has led to a further downturn in stock prices

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Malin Corporation Shares Jump 37% on Roche Acquisition of PoseidaMalin Corporation, a Dublin-based life sciences investment firm, experienced a significant rise in its share price following the news that Roche, a Swiss pharmaceuticals giant, has agreed to acquire Poseida, a Nasdaq-listed biopharma company in which Malin holds a 12% stake, for up to $1.5 billion.
Source: IrishTimes - 🏆 3. / 98 Read more »